GaiaLab independently ranked sunitinib as a top-tier candidate for glioblastoma using only its molecular mechanism. It turns out at least ten real clinical trials tested exactly that. Here is what that does — and does not — prove.
Sunitinib (Sutent) is FDA-approved for renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. It is not approved for glioblastoma — an aggressive brain cancer with few effective options and a grim prognosis.
The two share no indication. A system that matches drugs to diseases by name or label would never connect them. Any link has to come from the underlying biology.
Given a glioblastoma gene panel, GaiaLab scored sunitinib as a Tier I repurposing candidate — its highest tier — at 87 out of 100. The score was driven by two glioblastoma driver genes in the panel, not by any indication match.
Recorded rationale: target genes PDGFRA and PTEN. GaiaLab scores across six evidence dimensions; the driving factors are shown.
GaiaLab bridged an approved kidney-cancer drug to brain cancer through the multi-target kinase and angiogenesis logic a pharmacologist would use — reaching a genuine repurposing hypothesis, not a label lookup.
This was not merely plausible. GaiaLab's twelve linked trials were re-verified against the live ClinicalTrials.gov registry, requiring each to genuinely test sunitinib in glioblastoma. Ten of the twelve held up — six of them Phase 2 studies.
| Trial | Design | Status | Focus |
|---|---|---|---|
| NCT01100177 | Phase 2 | Completed | Sunitinib before/during radiotherapy, newly diagnosed GBM |
| NCT00499473 | Phase 2 | Completed | Sunitinib in recurrent malignant glioma |
| NCT00606008 | Phase 2 | Completed | Sunitinib for recurrent glioblastoma |
| NCT00864864 | Early Phase 1 | Completed | Sunitinib tumor-level pharmacology in GBM |
| NCT02928575 | Phase 2 | Reported | Sunitinib + temozolomide + radiation |
| NCT03025893 | Phase 2/3 | Reported | High-dose intermittent sunitinib |
| NCT00535379 | Phase 2 | Reported | Sutent in recurrent/progressive GBM |
| NCT00923117 | Phase 2 | Terminated | Sunitinib for recurrent brain cancer |
Eight representative trials shown; the live ClinicalTrials.gov registry lists 12 sunitinib-intervention glioblastoma trials in total. Method: each linked NCT record was re-checked against the live registry to confirm the intervention lists sunitinib and the condition is glioblastoma or an equivalent glioma term.
This is retrospective concordance, not a forward prediction. These trials predate the analysis; GaiaLab did not call them before they existed. What it demonstrates is narrower and still meaningful: GaiaLab's mechanism-based scoring reflects real therapeutic reasoning — it independently reached a hypothesis experienced clinicians independently chose to test — rather than surfacing noise.
And most of these sunitinib-glioblastoma trials did not succeed. Glioblastoma is punishing; a sound mechanistic rationale is not the same as clinical efficacy. GaiaLab tells you where to look, not what will work. Stating that plainly is what separates an honest instrument from a hype machine.
A recent independent corroboration. In 2025, a study in Cell reported that combining a myosin-II inhibitor (MT-125) with sunitinib significantly improved survival in orthotopic glioblastoma models over either agent alone (Kenchappa RS et al., Cell 2025;188(17):4622–4639; PMID 40499543). This is concordance, not prediction: the paper post-dates our analysis, and we make no priority claim. It is included only as an example of active experimental work converging on the same PDGFR-directed mechanism — the reasoning GaiaLab reached from molecular biology alone remains an area of live investigation, not a settled result.
The value isn't that GaiaLab was right about sunitinib curing brain cancer — it wasn't, and neither were the trials. It's that a mechanism-first score, computed with no indication data, landed on the same hypothesis the field spent a decade testing. That is the signal worth building on: the reasoning is sound, so the real question is whether it holds prospectively — a test GaiaLab has now publicly pre-registered.
See GaiaLab's mechanism-based scoring on your genes of interest — with every claim linked to primary literature and cross-referenced against ClinicalTrials.gov. Free, no account required.
Start an analysis →